Study of RGL-270 with or without Adebelimab for high-risk solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment (RGL-270) alone or with another drug (Adebelimab) to prevent cancer from coming back after surgery. It is for people with solid tumors that have a high chance of returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove a solid tumor and are at high risk of it coming back
- You are between 18 and 75 years old
- You have finished standard treatments after surgery, or you cannot have them
- You are able to provide tumor and blood samples for testing
- You agree to use contraception for 6 months after your last treatment
- Your cancer has no signs of return on scans within 14 days before first vaccine dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This trial tests a new drug called GB268, which is designed to help your immune system fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.